<code id='BD165FF3C7'></code><style id='BD165FF3C7'></style>
    • <acronym id='BD165FF3C7'></acronym>
      <center id='BD165FF3C7'><center id='BD165FF3C7'><tfoot id='BD165FF3C7'></tfoot></center><abbr id='BD165FF3C7'><dir id='BD165FF3C7'><tfoot id='BD165FF3C7'></tfoot><noframes id='BD165FF3C7'>

    • <optgroup id='BD165FF3C7'><strike id='BD165FF3C7'><sup id='BD165FF3C7'></sup></strike><code id='BD165FF3C7'></code></optgroup>
        1. <b id='BD165FF3C7'><label id='BD165FF3C7'><select id='BD165FF3C7'><dt id='BD165FF3C7'><span id='BD165FF3C7'></span></dt></select></label></b><u id='BD165FF3C7'></u>
          <i id='BD165FF3C7'><strike id='BD165FF3C7'><tt id='BD165FF3C7'><pre id='BD165FF3C7'></pre></tt></strike></i>

          Home / comprehensive / comprehensive

          comprehensive


          comprehensive

          author:fashion    Page View:35
          Adobe

          LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

          The deal includes up to another $400 million in payments if certain milestones are met.

          advertisement

          Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In